©The Author(s) 2025.
World J Gastroenterol. Dec 28, 2025; 31(48): 113856
Published online Dec 28, 2025. doi: 10.3748/wjg.v31.i48.113856
Published online Dec 28, 2025. doi: 10.3748/wjg.v31.i48.113856
Table 3 Multivariable Cox regression analyses of overall survival in the training cohort
| Variable | β estimate (95%CI) | HR (95%CI) | P value |
| PVTT (present vs absent) | 1.005 (0.481-2.099) | 0.844 | |
| Child stage (B vs A) | 0.857 (0.400-1.835) | 0.481 | |
| AFP, ng/mL (> 100 vs ≤ 100) | 0.947 (0.229-1.665) | 2.579 (1.258-5.285) | 0.010 |
| ALP, U/L (> 120 vs ≤ 120) | 0.804 (0.120-1.149) | 2.234 (1.127-4.430) | 0.021 |
| DBIL, μmol/L (> 7.3 vs ≤ 7.3) | 1.075 (0.297-1.853) | 2.931 (1.346-6.382) | 0.007 |
| NLR (> 2.5 vs ≤ 2.5) | 1.140 (0.325-1.955) | 3.127 (1.384-7.063) | 0.006 |
- Citation: Zhang X, Liao MJ, Ren LY, Qin WY, Mu SW, She SP, Fei R, Cong X, Zhou YP, Chen DB, Chen HS. AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma. World J Gastroenterol 2025; 31(48): 113856
- URL: https://www.wjgnet.com/1007-9327/full/v31/i48/113856.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i48.113856